Table 4 The subgroup analysis for ORR in patients with PROC

Combination therapeutic agents

Chemotherapy

2.97[1.89,4.67]

0.000

39.9%

0.125

PARP inhibitors

0.30[0.09,1.01]

0.051

-

-

Trial phase

phase II

2.22[1.03, 4.75]

0.041

72.7%

0.001

phase III

3.10[1.79,5.38]

0.000

-

-

Region

non-Asia

2.36[1.01,5.49]

0.047

72.8%

0.005

Asia

2.31[0.77,6.91]

0.136

75%

0.018

ECOG

0–2

3.14[1.87,5.27]

0.000

47.3%

0.091

0–4

0.82[0.12,5.45]

0.836

82.8%

0.016

Primary tumor site

OC, FTC, PC

2.80[1.34,5.84]

0.006

71.3%

0.004

OC

1.37[0.63,2.95]

0.427

22.3%

0.257

Publication year

within 5 years

2.02[0.83,4.91]

0.119

75.9

0.001

5 years ago

3.24[2.00,5.25]

0.000

0%

0.745